Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

  • receive the eCopy two days prior to the printed edition.
  • can partake in our online MCQs.
  • can enter our online sports quiz. is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

You are reading 1 of 2 free-access articles allowed for 30 days

Huge increase in Irish patients using the EU Cross-Border Healthcare Directive

By Mindo - 24th Jan 2018 | 34 views

In 2017, reimbursements processed under the directive rose to 2,011, at a cost of €4.4 million to the HSE. The figures for 2017 are full-year figures, according to the HSE, but are subject to change as patients submit documents in arrears, which means costs could increase further.

A total of 1,025 reimbursements in 2016 were approved by the HSE at a cost of €1.4 million, while in 2015, some 150 reimbursements were processed at a value of €542,000.

In 2014, when the scheme was first introduced that June, just seven reimbursements were processed by the HSE, at a cost €29,000.

Northern Ireland, France, Poland, Lithuania and Latvia are the most commonly-used countries under the directive, stated the HSE.

It has also emerged that a number of European citizens living in Ireland are using the CBD to access care in their home countries.

As awareness of the CBD continues to increase, along with the ongoing lengthy hospital waiting lists, now totalling almost 700,000 for inpatient and outpatient procedures across the HSE, the number of patients using the directive looks set to rise further in the future.

However, some GPs have raised concern over referring patients under the directive, citing potential medico-legal risks, and the lack of discharge protocols and follow-up care.

The CBD offers patients the option of receiving healthcare in another EU or European Economic Area (EEA) country, and covers treatments that are publicly-funded and available in Ireland, including inpatient and outpatient treatments.

Some services are not included, however, including organ transplantation, long-term care, nursing home care and public health initiatives.

The cost of the treatment is refunded to the patient by the HSE, but travel, accommodation and other costs are not refundable. It is unlike the Treatment Abroad Scheme, which covers treatments that are not available in Ireland, and may also cover some travel costs.

<strong><em>See feature pages 4-5</em></strong>

Leave a Reply

Latest Issue
The Medical Independent 9th May 2022

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read